269 related articles for article (PubMed ID: 24689883)
1. Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
Fukuda H; Numata K; Moriya S; Shimoyama Y; Ishii T; Nozaki A; Kondo M; Morimoto M; Maeda S; Sakamaki K; Morita S; Tanaka K
Radiology; 2014 Aug; 272(2):598-604. PubMed ID: 24689883
[TBL] [Abstract][Full Text] [Related]
2. Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria.
Takuma Y; Takabatake H; Morimoto Y; Toshikuni N; Kayahara T; Makino Y; Yamamoto H
Radiology; 2013 Dec; 269(3):927-37. PubMed ID: 24086071
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Kan X; Jing Y; Wan QY; Pan JC; Han M; Yang Y; Zhu M; Wang Q; Liu KH
Eur Rev Med Pharmacol Sci; 2015; 19(2):247-55. PubMed ID: 25683938
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
[TBL] [Abstract][Full Text] [Related]
5. Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Erös de Bethlenfalva-Hora C; Mertens JC; Piguet AC; Kettenbach J; Schmitt J; Terracciano L; Weimann R; Dufour JF; Geier A
Clin Sci (Lond); 2014 Feb; 126(3):243-52. PubMed ID: 23822114
[TBL] [Abstract][Full Text] [Related]
6. Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation.
Zhu K; Huang J; Lai L; Huang W; Cai M; Zhou J; Guo Y; Chen J
Radiology; 2018 Jul; 288(1):300-307. PubMed ID: 29688153
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of radiofrequency ablation to treat advanced hepatocellular carcinoma].
Wu J; Chen MH; Yang W; Wu W; Yan K
Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):256-60. PubMed ID: 22964144
[TBL] [Abstract][Full Text] [Related]
8. Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.
Bockorny B; Bullock AJ; Abrams TA; Faintuch S; Alsop DC; Goldberg SN; Ahmed M; Miksad RA
Dig Dis Sci; 2022 Jul; 67(7):3455-3463. PubMed ID: 34297268
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous CT-guided Radiofrequency Ablation for Lymph Node Oligometastases from Hepatocellular Carcinoma: A Propensity Score-matching Analysis.
Pan T; Xie QK; Lv N; Li XS; Mu LW; Wu PH; Zhao M
Radiology; 2017 Jan; 282(1):259-270. PubMed ID: 27399327
[TBL] [Abstract][Full Text] [Related]
10. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion.
Kim YS; Lee WJ; Rhim H; Lim HK; Choi D; Lee JY
AJR Am J Roentgenol; 2010 Sep; 195(3):758-65. PubMed ID: 20729457
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
Xu M; Xie XH; Xie XY; Xu ZF; Liu GJ; Zheng YL; Huang GL; Wang W; Zheng SG; Lü MD
Acta Radiol; 2013 Mar; 54(2):199-204. PubMed ID: 23171528
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy.
Yamasaki T; Kurokawa F; Shirahashi H; Kusano N; Hironaka K; Okita K
Cancer; 2002 Dec; 95(11):2353-60. PubMed ID: 12436442
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
Giorgio A; Merola MG; Montesarchio L; Merola F; Santoro B; Coppola C; Gatti P; Amendola F; DI Sarno A; Calvanese A; Matteucci P; Giorgio V
Anticancer Res; 2016 Nov; 36(11):6179-6183. PubMed ID: 27793949
[TBL] [Abstract][Full Text] [Related]
15. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
[TBL] [Abstract][Full Text] [Related]
16. Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
Tang Z; Kang M; Zhang B; Chen J; Fang H; Ye Q; Jiang B; Wu Y
Tumori; 2017 May; 103(3):286-291. PubMed ID: 28058713
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial.
Zhang YJ; Liang HH; Chen MS; Guo RP; Li JQ; Zheng Y; Zhang YQ; Lau WY
Radiology; 2007 Aug; 244(2):599-607. PubMed ID: 17641378
[TBL] [Abstract][Full Text] [Related]
18. Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis.
Nishikawa H; Osaki Y; Endo M; Takeda H; Tsuchiya K; Joko K; Ogawa C; Taniguchi H; Orito E; Uchida Y; Izumi N;
Int J Oncol; 2014 Dec; 45(6):2295-302. PubMed ID: 25230744
[TBL] [Abstract][Full Text] [Related]
19. Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma.
Yamasaki T; Kurokawa F; Shirahashi H; Kusano N; Hironaka K; Okita K
Cancer; 2001 Apr; 91(7):1342-8. PubMed ID: 11283935
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
